Vanda amends bylaws to adopt universal proxy rule procedures

Vanda Pharmaceuticals Inc.

Board approved restated bylaws on Dec 13, 2023, effective immediately.
Amendments address Rule 14a-19 universal proxy requirements, including 67% voting power solicitation requirement.
Bylaws conform to recent Delaware General Corporation Law changes on adjournment and stockholder lists.
Other technical non-substantive changes included in the restated bylaws.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Vanda Pharmaceuticals Inc.: Amended and restated bylaws to address Universal Proxy Rules and conform to Delaware law (effective 2023-12-13).

Change: bylaw amendment
Effective: 2023-12-13

Exact text from the filing

On December 13, 2023, the Board of Directors of Vanda Pharmaceuticals Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Fourth Amended and Restated Bylaws (the “Bylaws”).

View on SEC.gov

Browse all governance changes →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-296659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.